

Medicines Optimisation Advice Bulletin – October 2025

For the attention of primary and secondary care staff involved in patient care

Initiation of Inclisiran in Primary and Secondary Care

Inclisiran is an injectable treatment which is NICE-approved for treating primary hypercholesterolaemia or mixed dyslipidaemia, as per [NICE TA733 \(October 2021\)](#).

It is included in our local clinical guideline, and our lipidology and cardiology clinicians support its use in line with this.

The links to this guidance, as well as further prescribing information, are available on [Netformulary](#)

Norfolk and Waveney ICB policy is that this is classified as **AMBER ADVICE - Specialist advice required from clinician with relevant expertise prior to initiation**. This means that any cardiologist, lipidologist, endocrinologist or GP with specialist interest and experience can recommend this for initiation within primary care. *It is restricted for use only in those patients who meet the criteria listed in the NICE guidance.* It is the specialists' responsibility to ensure that they make such recommendations in line within this guidance. There is no requirement and no plan for a requirement for this to be initiated in secondary care.

We would like to encourage the prescribing of Inclisiran as per [NICE TA733 \(October 2021\)](#), and are keen to hear of any issues relating to its use.

Inclisiran is recommended only if:

- there is a history of any of the following cardiovascular events:
 - acute coronary syndrome (such as myocardial infarction or unstable angina needing hospitalisation)
 - coronary or other arterial revascularisation procedures
 - coronary heart disease
 - ischaemic stroke or
 - peripheral arterial disease, and
- low-density lipoprotein cholesterol (LDL-C) concentrations are persistently 2.6 mmol/l or more, despite maximum tolerated lipid-lowering therapy, that is:
 - maximum tolerated statins with or without other lipid-lowering therapies or,
 - other lipid-lowering therapies when statins are not tolerated or are contraindicated

Please email the medicines optimisation team if you are concerned that patients have struggled to have their prescription issued in the community after appropriate advice has been given - nwicb.medsqueries@nhs.net. Please also let the team know if you think that Inclisiran has been recommended outside of NICE guidance.

Many thanks for your support.

Dr Frankie Swords (she/her)
Executive Medical Director and Caldicott Guardian
Norfolk and Waveney Integrated Care Board

On behalf of the Norfolk and Waveney Therapeutics Advisory Group